With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Commentary|Articles|May 20, 2026
Stay Ahead of ASCO 2026: See What Gynecologic Oncologists Are Prioritizing
Author(s)Caroline Seymour
Fact checked by: Courtney Flaherty
Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.
Advertisement
Advertisement
As the oncology community prepares to convene in Chicago for the 2026 ASCO Annual Meeting, OncLive® asked gynecologic oncology experts to identify the presentations they anticipate will drive discussion, inform practice, and spotlight emerging advances in the treatment of patients with gynecologic cancers.
Related to this article
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Advertisement
Advertisement